Clinical Trial Update: Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers [Phase 2]

View source ↗

Summary

This clinical trial update summarizes long-term safety data for pirtobrutinib in participants with previously treated blood cancers from a Phase 2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING